HC Wainwright Reiterates Buy Rating for Gain Therapeutics (NASDAQ:GANX)

HC Wainwright reiterated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a research note issued to investors on Tuesday, Benzinga reports. HC Wainwright currently has a $8.00 price objective on the stock.

Several other analysts have also recently weighed in on GANX. Chardan Capital reiterated a buy rating and issued a $6.00 price objective on shares of Gain Therapeutics in a research note on Friday, August 9th. Oppenheimer reaffirmed an outperform rating and set a $8.00 price target on shares of Gain Therapeutics in a report on Wednesday, August 14th.

Gain Therapeutics Stock Performance

Shares of GANX opened at $1.05 on Tuesday. The firm has a 50-day moving average of $1.16 and a 200-day moving average of $2.44. Gain Therapeutics has a one year low of $0.89 and a one year high of $5.33. The company has a market cap of $18.95 million, a PE ratio of -0.70 and a beta of 0.35. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.84 and a quick ratio of 2.84.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.11). As a group, equities analysts forecast that Gain Therapeutics will post -1.05 earnings per share for the current year.

Insiders Place Their Bets

In other Gain Therapeutics news, Chairman Khalid Islam bought 50,000 shares of Gain Therapeutics stock in a transaction on Friday, August 9th. The shares were purchased at an average cost of $1.00 per share, with a total value of $50,000.00. Following the acquisition, the chairman now directly owns 50,000 shares of the company’s stock, valued at approximately $50,000. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have acquired 81,400 shares of company stock valued at $85,284 in the last ninety days. 11.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Gain Therapeutics

A number of institutional investors have recently modified their holdings of GANX. Warberg Asset Management LLC acquired a new position in shares of Gain Therapeutics during the 2nd quarter valued at $66,000. Renaissance Technologies LLC raised its holdings in Gain Therapeutics by 154.2% during the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after buying an additional 72,000 shares during the last quarter. Finally, Hohimer Wealth Management LLC bought a new stake in shares of Gain Therapeutics in the 2nd quarter worth $422,000. 11.97% of the stock is owned by institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.